# Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma

> **NCT06909877** · PHASE1,PHASE2 · RECRUITING · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)

## Interventions

- **DRUG:** HH2853 Tablets

## Key facts

- **NCT ID:** NCT06909877
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-27
- **Primary completion:** 2025-10-31
- **Final completion:** 2027-07-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06909877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06909877, "Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06909877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*